ArgentSE, HillSA: The novel use of clozapine in an adolescent with borderline personality disorder. Therap Adv Psychopharmacol, 4:149–155, 2014.
2.
De LeonJ, RuanC, SchoretsanitisG, De Las CuevasC: A Rational use of clozapine based on adverse drug reactions, pharmacokinetics, and clinical pharmacopsychology. Psychother Psychosom. 1–15, 2020. DOI:10.1159/000507638
3.
HamodaHM, OsserDN: The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An update on psychotic depression. Harv Rev Psychiatry, 16:235–247, 2008.
4.
OlssonE, EdmanG, BertilssonL, HukicDS, LavebrattC, ErikssonSV, ÖsbyU: Genetic and clinical factors affecting plasma clozapine concentration. Prim Care Companion CNS Disord. 17, 2015. DOI:10.4088/PCC.14m01704
5.
RasmussenKG: Do patients with personality disorders respond differentially to electroconvulsive therapy?. J ECT, 31:6–12, 2015.
6.
RiesselmanA, JohnsonE, PalmerE: Lithium and clozapine in suicidality: Shedding some light to get out of the dark. Mental Health Clin, 5:237–243, 2015.
7.
RohdeC, PolcwiartekC, CorrellCU, NielsenJ: Real-world effectiveness of clozapine for borderline personality disorder: Results from a 2-year mirror-image study. J Personal Disord, 32:823–837, 2018.
8.
WardenD, RushAJ, TrivediMH, FavaM, WisniewskiSR: The STAR*D project results: A comprehensive review of findings. Curr Psychiatry Rep, 9:449–459, 2007.
